NCT07279844Not yet recruiting
An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection in Patients With Primary Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 12 Dec 2025
Brief summary (registry, in English)
To evaluate the long-term safety of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 6 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 15 Dec 2025
- Primary completion date
- 14 Dec 2029
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07279844
What you commit to
- Study type: Observational
- Planned participants: 6
- From 15 Dec 2025 to the primary completion date, 14 Dec 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
- \-
Who the study is looking for
- Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treatment；
- Those who voluntarily participate in this trial and sign a written informed consent form -
Age in the registry: 45 years to 70 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.